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Context: Geoffrey Rose’s two principal approaches to public health intervention
are (1) targeted strategies focusing on individuals at a personal increased risk of
disease and (2) population-wide approaches focusing on the whole population.
Beyond his discussion of the strengths and weaknesses of these approaches,
there is no empiric work examining the conditions under which one of these
approaches may be better than the other.
Methods: This article uses mathematical simulations to model the benefits and
costs of the two approaches, varying the cut points for treatment, effect magni-
tudes, and costs of the interventions. These techniques then were applied to the
specific example of an intervention on blood pressure to reduce cardiovascular
disease.
Findings: In the general simulation (using an inverse logit risk curve), lower
costs of intervention, treating people with risk factor values at or above where
the slope on the risk curve is at its steepest (for targeted interventions), and
interventions with larger effects on reducing the risk factor (for population-
wide interventions) provided benefit/cost advantages. In the specific blood
pressure intervention example, lower-cost population-wide interventions had
better benefit/cost ratios, but some targeted treatments with lower cutoffs
prevented more absolute cases of disease.
Address correspondence to: Sandro Galea, Department of Epidemiology, University
of Michigan School of Public Health, 109 Observatory St, Room 3663, Ann
Arbor, MI 48109-2029 (email: sgalea@umich.edu).
The Milbank Quarterly, Vol. 86, No. 4, 2008 (pp. 581–600)
c© 2008 Milbank Memorial Fund. Published by Wiley Periodicals Inc.
581
582 J. Ahern, M.R. Jones, E. Bakshis, and S. Galea
Conclusions: These simulations empirically evaluate some of Rose’s original
arguments. They can be replicated for particular interventions being considered
and may be useful in helping public health decision makers assess potential
intervention strategies.
Keywords: Population health, intervention studies, computer simulation,
cardiovascular diseases.
Geoffrey Rose’s work introduced an important ideainto our thinking about etiology (Rose 1992, 2001). Hepointed out that some etiologic research seeks to understand the
causes of cases, trying to find out why certain individuals have disease.
Other research attempts to uncover the causes of incidence, identify-
ing the reasons that some populations have higher rates of disease. The
causes of cases are those exposures that vary within a population, whereas
the causes of incidence are the exposures that vary between populations.
Whether exposures vary similarly within and among populations deter-
mines whether they are identified as causes of cases, causes of incidence,
or both.
In the context of disease prevention and health promotion, a focus
on the causes of cases leads to a different intervention approach than
does a focus on the causes of incidence (Rose 1992, 2001). If causes of
cases are the focus, then a targeted intervention strategy is implemented,
identifying individuals at a personal increased risk of disease and offering
treatment to reduce that risk. But if causes of incidence are the focus,
then exposures across the entire population are modified to reduce the
rate of disease across the whole population.
Each of these two approaches has strengths and weaknesses (Rose
1992, 2001). The targeted approach is appropriate to the individuals
treated, because it is specific to their current risk factors, their motivation
thus tends to be higher, and if there is any risk to the treatment, the
benefit-to-risk ratio will be higher among those at a higher risk of
disease. But the targeted approach requires ongoing screening to identify
those at high risk; it does not deal with the root of the problem, and
thus intervention for those at high risk must continue indefinitely;
this approach does not reduce the burden of disease as much as one
might expect, because most cases frequently come from the large number
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of people in the population at lower risk of disease; and the targeted
approach is behaviorally inappropriate because it asks people to make
different choices, even though the norms of their social group remain
unchanged.
In contrast, intervention strategies that target the whole population
deal with the root of the problem by removing the underlying causes
of disease across the population, dramatically reduce the disease bur-
den because shifting risk levels for all members of the population even
slightly can greatly alleviate the burden of disease, and are behaviorally
appropriate because they alter the social norms (or other exposures) so
that “normal” behavior becomes lower risk. Nonetheless, intervention
strategies also have difficulties, including a small benefit to any individ-
ual (the so-called prevention paradox), with motivation correspondingly
lower; and if there is any risk to the treatment, the benefit-to-risk ratio
will be lower for those who initially were at lower risk of the disease.
Rose concludes that both targeted and population-wide approaches
to prevention will continue to be necessary. He emphasizes, however,
the importance of seeking and intervening in the causes of incidence,
due to the potential for a dramatic and long-lasting reduction of the
disease burden (Rose 1992, 2001). These ideas have been one of the
motivations for the growing research on exposures that vary among
populations, including research on community- or neighborhood-level
exposures (Diez Roux 2004; Duncan, Jones, and Moon 1998; Macintyre,
Ellaway, and Cummins 2002). These ideas also have provided support
for the greater number of interventions targeting population-level expo-
sures, such as norms (Merzel and D’Afflitti 2003). The limited success
of several high-profile targeted intervention programs also has spurred
movement toward population-wide intervention strategies (Syme 1996).
Rose’s presentation of the two approaches to prevention provides a
useful heuristic that can guide public health intervention planning. It
does not, however, provide empiric guidance about when, and under
what circumstances, targeted or population-wide approaches may be
more desirable. For this article, in response to the issues laid out by
Rose for assessing the best approach to intervention in specific situa-
tions, we quantified the benefits of preventing disease and the costs of
treating disease for both the targeted and population-wide approaches,
given the different costs of the interventions, the levels at which treat-
ment is applied (cut points) for the targeted approach, and the magni-
tudes of the effect of reducing the risk factor for the population-wide
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approach. To illustrate this approach, we used the specific example
of potential interventions on blood pressure to reduce cardiovascular
disease, and we also provide a quantitative approach that could be ap-




We started by simulating a population distributed across a contin-
uous risk factor (examples of continuous risk factors might include
blood pressure, cholesterol, and the like). Although simulations could
be conducted with more than one risk factor, for this article and for
simplicity and clarity, we restricted ourselves to only one. The simu-
lated population had a normal distribution across the continuous risk
factor with a mean of 10 and a standard deviation (SD) of 2. We then
applied an intervention to the population, meaning that we shifted
the total population’s distribution across the risk factor in some way.
This is akin to treating people before they develop disease, based
solely on their current risk factor value. The two types of inter-
ventions we considered were targeted treatment and population-wide
treatment, based on Rose’s original discussion. In the targeted treat-
ment, members of the population above a threshold or cut-point level of
the risk factor were “treated,” and their risk factor values were reduced
by a fixed amount. In the simulation, the threshold selected was 12 (1 SD
above the mean), and the risk factor values were reduced by 2 (1 SD) for
those treated. In the population-wide treatment, all members of the pop-
ulation were “treated,” and the risk factor levels of the entire population
were reduced by a fixed amount. In the simulation, all risk factor values
were reduced by 0.5 (0.25 SD). A range of values around these “fixed”
values were considered in different simulations. These values were based
on a general scenario in which the targeted treatment would be intensive
and potentially pharmacological and would produce a large change in the
risk factor for those treated. Conversely, the population-wide treatment
was modeled to represent a diffuse and nonpharmacological interven-
tion that would produce a more modest change in the risk factor for
the whole population. By using this method, we could compare both
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targeted and population-wide treatments of any magnitude, depending
on the expected effects of specific potential interventions.
We then multiplied the risk curve by the simulated population before
treatment and after targeted or population-wide treatment. Multiplying
the risk curve by the pretreatment population and integrating the dis-
tribution calculates the expected amount of disease after the duration,
given the risk curve and no treatment. Multiplying the risk curve by
either posttreatment population and integrating the distribution calcu-
lates the expected amount of disease after the duration, given a particular
treatment. We next compared the incidence of disease in both treated
populations with the incidence of disease in the untreated population.
As a next step, we added to the model the total cost, total benefit, and
a benefit/cost ratio for each intervention by assigning an average cost
per person treated and an average benefit per case of disease prevented.
After examining the costs of a wide range of prescription medications,
we started with a cost of $1,000 per person, a representative cost for the
targeted treatment of hypertension using a range of widely prescribed
hypertension medications plus routine follow-up (Murray et al. 2003;
Odell and Gregory 1995; Pearce et al. 1998). For the population-wide
treatment, we started with a cost of $200 per person, again a repre-
sentative cost based on literature on the cost of population-based inter-
ventions (Murray et al. 2003). A range of values around these starting
values were considered in different simulations. The benefit of avoiding
a case was set at $30,000, based on the average cost of a major cardiac
event (Lindgren et al. 2005, 2007). However, any values of cost or ben-
efit could be applied using this simulation method, depending on the
actual interventions being considered and compared. We focused here
on the comparison of the benefit/cost ratios of different intervention
approaches by calculating the benefit/cost ratio of one intervention and
dividing it by the benefit/cost ratio of another intervention. This ratio of
benefit/cost ratios favors the numerator intervention when the value is
above 1 and values the denominator intervention when it is below 1. In
all our analyses, we considered population-wide benefit/cost ratios in the
numerator; hence a ratio greater than 1 suggests that population-wide
interventions have more favorable benefit/cost ratios than do targeted
interventions, and vice versa. The interventions are equally monetarily
efficient at 1. Note that this method need not use this measure, that
interventions could be compared with cost/case-prevented ratios or other
measures of interest using this simulation method.
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Varying the input parameters in the simulation produces a range
of benefit/cost ratios. The initial conditions varied in this article were
the cost of the intervention (for the targeted and population-wide ap-
proaches), the cut point above which people were treated (for the targeted
approach), and the magnitude of the shift effect on reducing the risk
factor (for the population-wide approach). We plotted the benefit/cost
ratios and ratio of benefit/cost ratios as surfaces in which two of the
initial conditions were varied along each of the x and y axes.
Specific Example
In the second part of the analysis, we considered blood pressure as the
risk factor and the outcome cardiovascular disease as a specific example
of how this simulation method could be used when comparing two
concrete potential interventions. We used the Framingham risk equation
to generate a risk curve for blood pressure based on empirical research
(Kannel, McGee, and Gordon 1976). The risk curve (log odds intercept,
log odds slope) for systolic blood pressure was calculated for a smoker,
aged fifty, with serum cholesterol of 6.37 mmol/l, no glucose intolerance,
and no left ventricular hypertrophy (LVH) (Kannel, McGee, and Gordon
1976). The need to specify the age, smoking status, serum cholesterol,
glucose intolerance, and LVH arose from the need, for simplicity, to have
one risk curve for the whole population. Simulations could be extended
to accommodate additional characteristics that modify risk, and we will
describe such extensions in a future article.
We then simulated variations of the targeted approaches to the treat-
ment of blood pressure and of population-wide interventions to lower
blood pressure and observed their implications for the benefit/cost ra-
tios and ratios of benefit/cost ratios for the two intervention approaches.
The total population values for blood pressure (total mean 130.3, total
SD 16.5) were obtained from a population-based study (Weinehall et al.
1999). For the targeted approach, we varied the cut point for treatment,
and for the population-wide approach, we varied the cost per person.
The effect of the targeted treatment on the reduction in blood pressure
among those treated was 2.88 SD (Rx effect) and was estimated from the
results from the Systolic Hypertension in the Elderly Program (SHEP)
study (SHEP Cooperative Research Group 1991). The cost per person
treated for the targeted intervention was calculated as $1,200, which is
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TABLE 1
Parameters of the Models
Parameters Basic Assumptions Source
Total peoplea,b 100,000 Hypothetical population
size
Total meana,b 130.3 mmHg (Weinehall et al. 1999)
Total SDa,b 16.5 (Weinehall et al. 1999)
Log odds intercepta,b −5.768 (Kannel, McGee, and
Gordon 1976)
Log odds slopea,b 0.016 (Kannel, McGee, and
Gordon 1976)
Treatment cutoff a 120 . . . 170 (Chobanian et al. 2003)
Rx effecta 47.59 mmHg (2.88 SD) (SHEP Cooperative
Research Group 1991)
Cost per person treateda $1,200 (Pearce et al. 1998)
Total shift effectb 8.4 mmHg (0.51 SD) (Appel et al. 1997)
Cost per personb $20–$220 (Murray et al. 2003)
Notes: aTargeted approach.
bPopulation approach.
the cost of a common blood pressure medication taken over eight years
(Pearce et al. 1998). For the population-wide approach, the effect of a
population-wide dietary intervention on the reduction in blood pressure
was 0.51 SD across the population and was estimated from the Dietary
Approaches to Stop Hypertension (DASH) study (Appel et al. 1997).
The cost per person of a population intervention was considered across
a range of values suggested by various completed population-based in-
terventions (Murray et al. 2003). Table 1 shows the specific parameters
used in this simulation and their sources.
The outputs of each of the analyses include the cost per case prevented
(cost per case prevented), the fraction of the total population treated
for the targeted intervention (total treated), the fraction of the total
population in which disease was prevented (benefit fraction), the fraction
of the population that would have had disease but that was prevented
(disease prevented), the total cost of the treatment (total cost), the total
benefit of the treatment (monetary benefit), and the benefit-to-cost ratio
(benefit/cost), which were produced by the methods described earlier.
All simulations and analyses were conducted using Maple v.11 (code is
available from the corresponding author on request).
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Results
General Simulation
The figures depict the results of simulations using a logistic risk curve
(logistic risk curve equation: 1/ (1 + exp(4 – 0.3 ∗ x))), varying aspects
of the intervention (treatment cut point for the targeted approach, mag-
nitude of shift effect for the population-wide approach), and cost (cost
per person treated for both approaches). The two types of graphs depict
surfaces. Those graphs whose z axis is labeled “Benefit/cost ratio” show
a single treatment approach for various values of two input parameters.
In these graphs the approach is monetarily efficient if the z axis value is
larger than 1 (implying that benefit is greater than cost) and inefficient
if the z axis value is less than 1 (cost is greater than benefit). Those
graphs whose z axis is labeled “Ratio of benefit/cost ratios” compare the
population-wide (numerator) and the targeted (denominator) treatment
approaches.
Figure 1 shows the benefit/cost ratio surface for a targeted treatment
approach as both the cutoff for treatment and the average targeted
treatment cost per person are varied. The figure indicates that along the
treatment cutoff (Treatment cutoff) axis, the ratio reaches a maximum
at around 13. This is exactly where the logistic risk curve reaches its
maximum slope. As would be expected, across all cutoffs the benefit/cost
ratio increases as the cost per person treated decreases.
Figure 2 shows the ratio of benefit/cost ratios between a population-
wide approach and a targeted approach as the initial conditions of cost
per person and cutoff for treatment are varied for the targeted approach.
The values for the population-wide approach are fixed at 0.5 (0.25 SD)
for the magnitude of the shift effect and at $200 for the cost per person
treated; thus the population-wide approach benefit/cost ratio surface is
constant across the shown space. We can see the ratio of benefit/cost
ratios exceeding the 1 plane, favoring the population-wide approach
for costs of the targeted treatment exceeding $600 to $800 per person,
depending on the cutoff points (Treatment cutoff).
Figure 3 shows the benefit/cost ratio of a population-wide treatment as
the treatment effect and the cost per person are varied. The curve is above
1 almost everywhere, indicating that this population-wide approach is
cost effective on almost all the space shown. The curve has a 1/x shape
along the cost axis and an almost linear shape along the shift effect axis.
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figure 1. Targeted Intervention: Surface of Benefit in Cases Averted/Cost of
the Intervention for a Targeted Intervention as the Cost of the Intervention
(Cost/Person Treated) and the Cutoff for Treatment (Treatment Cutoff) Are
Varied
The 1/x shape along the cost axis demonstrates that the increase in the
benefit/cost ratio with a decreasing cost rises (accelerates) as the costs
fall.
Figure 4 shows the ratio of benefit/cost ratios between a population-
wide approach and a targeted approach as the initial conditions of cost
per person treated and the magnitude of the shift effect are varied for
the population-wide approach. The values for the targeted approach are
fixed at 12 for the treatment cutoff and at $1,000 as the cost per person
treated; thus the targeted approach benefit/cost ratio surface is constant
across the shown space. As the cost of the population-wide treatment
per person increases, the magnitude of the shift effect must be larger
for the population-wide approach to be favored. For example, when the
shift effect is 0.85 (0.425 SD), the cost must be $300 or lower to favor
the population-wide approach. In contrast, where the shift effect is 1.5
(0.725 SD), the cost can be as high as $500 per person and still favor the
population-wide approach.
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figure 2. Comparison of the Benefit/Cost of the Targeted Intervention and
the Population-Wide Intervention while Varying the Treatment Cutoff and the
Cost per Person Treated for the Targeted Intervention; Values Greater than 1
Favor the Population-Wide Treatment, and Values below 1 Favor the Targeted
Treatment
Specific Example
Having presented some hypothetical scenarios, we now move to the con-
crete example considering blood pressure as a risk factor for cardiovas-
cular disease. Table 2 presents some scenarios for targeted treatments,
presenting all of the inputs and some of the outputs when the total
population and the logistic risk curve are known. In table 2 we vary
the systolic blood pressure cutoff for treatment (Treatment cutoff) from
120 mmHg to 180 mmHg, which represent levels from prehyperten-
sive to extremely hypertensive (Chobanian et al. 2003). This affects the
number of people treated (total treated) and consequently affects the cost
of this treatment scheme (total cost) and the benefits of the treatment
(monetary benefit). We also see a difference in the fraction of the total
population in which disease is prevented (benefit fraction) and the frac-
tion of the population that would have had disease but that was prevented
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figure 3. Population-Wide Intervention: Surface of Benefit in Cases
Averted/Cost of the Intervention for a Population-Wide Intervention as the
Cost of the Intervention (Cost/Person Treated) and the Magnitude of the Effect
of Treatment on the Risk Factor (Total Shift Effect) Are Varied
(disease prevented). From the prehypertensive cutoff for treatment up
to the severe hypertensive cutoff, the fraction of the total population
in which disease was prevented (benefit fraction) ranges from 1.0 to
0.004 percent, and the fraction of the population that would have
had disease but that was prevented (disease prevented) ranges from
42.0 to 0.1 percent. These benefit measures favor the lowest cutoff
of 120 mmHg, although this approach is least efficient in terms of
benefit/cost. From the prehypertensive cutoff for treatment up to the
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figure 4. Comparison of the Benefit/Cost of the Population-Wide Interven-
tion and the Targeted Intervention while Varying the Cost of the Intervention
(Cost/Person Treated) and the Magnitude of the Effect of Treatment on the Risk
Factor (Total Shift Effect) for the Population-Wide Intervention; Values Greater
than 1 Favor the Population-Wide Treatment, and Values below 1 Favor the
Targeted Treatment
severe hypertensive cutoff, the benefit/cost increases from 0.348 up to
0.689.
Table 3 presents some scenarios for the population-wide intervention,
presenting all of the inputs and some of the outputs when the total
population and the logistic risk curve are known. Only the cost of
treatment per person is varied. The fraction of the total population in
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which disease was prevented (benefit fraction) is 0.3 percent, and the
fraction of the population that would have had disease but that was
prevented (disease prevented) is 12.1 percent. These values are constant,
since the treatment that produced these measures is not varied. Not
surprisingly, all the cost measures favor the lowest cost; the benefit/cost
ranges from 4.392 for the least expensive population-wide intervention
to 0.399 for the most expensive intervention.
Together, the tables can be used to examine the scenarios and ways
in which one treatment is better than the other. The population-wide
treatments costing $100 or less are more benefit/cost effective than any of
the targeted treatments. But some of the targeted treatments with lower
cutoffs for treatment provide more benefit for the benefit fraction and the
disease prevented. For higher costs of the population-wide treatment,
the cutoff chosen for blood pressure determines the relative benefit/cost
effectiveness of the two approaches. In all the targeted and population-
wide intervention scenarios, the benefit exceeds the cost for a population-
wide treatment only with a cost of $60 per person or less.
Discussion
In this analysis, we quantitatively considered the issue raised by Rose
about the relative benefits of a population-wide approach to intervention
compared with a targeted approach. We explored the two approaches
using simulations in which we varied aspects of the costs and treatment
effects for each intervention approach. Finally, we applied these meth-
ods to a specific example, comparing two approaches to intervention
regarding blood pressure to reduce cardiovascular disease.
In a series of general simulations, we found that either approach could
be favored, depending on the parameters of cost and treatment effect.
The targeted approaches tended to be favored when people were treated
if they had risk factor values at or above where the slope of the (inverse
logit) risk curve was at its steepest and the costs of treatment per person
could be kept low. Population-wide approaches tended to be favored
when the intervention had larger effects on reducing the risk factor and
the costs of treatment per person could be kept low. This suggests that
in any situation, both approaches should be considered. Simulations like
those presented here could be used to consider quantitatively the favora-
bility of one intervention approach over another if the input parameters
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for costs, the treatment cut points, and the effect magnitudes could be
estimated accurately for all exposures and outcomes of interest. Esti-
mates of such parameters are probably more readily available for areas
in which more intervention work has already been conducted. For a new
type of intervention, accurately estimating input parameters would be
a challenge, and a wider range of potential values would need to be
considered.
In our specific example, we used the risk curve for cardiovascular
disease based on the Framingham equation and applied it to a real
population distribution of blood pressure. We then applied a targeted
intervention and a population-wide intervention to blood pressure and
modeled the effects of each intervention on the change in blood pres-
sure distribution based on realistic values of blood pressure reductions
from medication (for the targeted approach) and from the results of a
population-wide intervention (for the population-wide approach). Fol-
lowing these interventions, we examined the change in cardiovascular
disease incidence. In addition, we varied the cut point for treatment
for the targeted approach and varied the cost per person treated for the
population-wide approach to examine which scenarios favored which
approach. The costs and benefits of the two approaches were then com-
pared. The results of this specific example suggested that for the targeted
scenarios, the most cost-effective measures typically provided the least
benefit and that for all targeted and population-wide interventions, only
a population-wide intervention with a very low cost produced more
benefit than cost.
One important additional consideration in comparing approaches,
which Rose suggested, is the length of time that the intervention will
be required (Rose 2001). By definition, the targeted approach will re-
quire screening for those at high risk and treatment of those at high risk
indefinitely into the future. In contrast, population-wide approaches are
intended to change the fundamental underlying causes of the risk factor,
so that after a certain period of time, those lower values of the risk factor
across the population would become the norm without further interven-
tion (at least in the ideal scenario). From this perspective, comparing the
cost of each intervention over the same time period may be misleading.
The time anticipated to be required for the population-wide intervention
could be incorporated into the cost/benefit calculations. These total costs
of a population-wide approach could be compared with the annual costs
of a targeted approach, offering an opportunity to determine how much
time would need to elapse before a population-wide approach became
Benefits and Costs of Population-Wide and Targeted Interventions 597
more cost effective than a targeted approach, even if a population-wide
approach were more expensive in any particular intervention year.
Preventing a case of disease also is not without cost. Even though the
cost of caring for one disease may be prevented, those who live longer
may have more need for long-term care. If such costs could be estimated
based on current medical expenditures for those living longer, these
potential costs could be integrated into this modeling approach.
The costs of screening for those at high risk of disease should also be
incorporated into models of the targeted approach, as people cannot be
treated until they have been identified as being in a high-risk group. In
our specific example, we considered only the costs of prescribing a blood
pressure medication, but the costs of screening at regular intervals could
be considered as well (Kristiansen, Eggen, and Thelle 1991). While these
costs may not be high for blood pressure and cardiovascular disease—at
least for those who receive regular medical checkups—it may be higher
for other diseases and their risk factors of interest.
For simplicity, we assumed that all individuals took their blood pres-
sure medication and that it had exactly the expected effect on everyone
who took it. We also assumed that everyone in the population-wide
intervention had the same reduction in blood pressure that was expected
based on an intervention, although it is important to note that this
reduction was observed in a situation in which the levels of participa-
tion in and compliance with the intervention were at their actual levels,
not some hypothetical maximum level. Both levels of compliance and
magnitudes of effect could be modified over a range of values and incor-
porated into the model, allowing estimation of more realistic benefits
and effects of interventions for real-world applications. Rose indicated
that people at high risk were typically more motivated but that for some
interventions (e.g., diet and exercise changes), they were being asked
to act in a way that was behaviorally unsuitable for their social con-
text (Rose 2001). He also noted that the population-wide approach may
be plagued by low motivation owing to the “prevention paradox” (Rose
2001). But if population-wide change does gain momentum, norms may
start to change, encouraging behavioral or other changes for everyone in
the population. The two competing issues for each type of intervention
would need to be considered on balance to estimate the potential net
effect on compliance and the magnitude of the effect.
In all these simulations, we assumed there was no negative effect
of treatment. However, for many real-world interventions, particularly
those involving medication but also for population-level interventions,
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there are substantial potential negative effects. The model could accord-
ingly be modified to allow negative outcomes among a certain percentage
of those treated, based on what is known about the medication or other
intervention with potential negative consequences.
This simulation examined the effects of reducing blood pressure on
cardiovascular disease, but reducing blood pressure clearly could affect
many different health outcomes (e.g., cerebrovascular disease). In ad-
dition, reducing blood pressure could also reduce complications from
its interaction with other conditions. To the extent that this is true,
the benefits of the intervention are likely underestimated using this
approach.
For risk factors with U-shaped or J-shaped associations with outcomes,
a reasonable approach to intervention would be targeting people with
both high and low values of the risk factor. In many respects, this is
how risk factors like body mass index have been handled. These types
of interventions could be modeled using the same techniques presented
here to determine which groups with high and low values of the risk
factor should be treated when also considering the costs and effects of
treatment.
One obvious concern about this simulation approach is that for any
particular relation between risk factor and health outcome, we typically
do not know the shape of the risk curve (i.e., how changing the risk
factor will precisely affect the likelihood of disease) at the same level
of precision as that of the curves specified in these simulations. Some
additional simulations (not presented here but available from the authors
on request), however, were reassuring in this regard. The simulations
suggested that for a range of different types of relations between risk
factors and health outcomes (i.e., different risk curve shapes such as
inverse logistic risk curve, U-shaped risk curve, and threshold risk curve),
the results were quite similar for curves of similar magnitude. Therefore,
if we can reasonably determine the more general form of the risk curve
and approximate the necessary parameters, the results should not be
misleading.
In conclusion, we presented a quantitative method for comparing the
results of potential interventions from the point of view of costs and
benefits, particularly comparing targeted approaches with population-
wide approaches. Our method builds on Rose’s work, particularly the
concepts he clearly laid out as the positives and negatives of these two
intervention strategies (Rose 1992, 2001). We also quantified some of
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these concepts to compare cost effectiveness and benefit in disease pre-
vention for real-world applications. In settings where resources are plen-
tiful, both targeted and population-wide interventions might be feasible;
comparing their strengths and weaknesses and determining the optimal
balance of costs and benefits for each approach would still be informative
in this situation. Although this work is computationally intensive, we
believe that such simulations hold promise for helping public health
decision makers evaluate potential intervention strategies and can moti-
vate researchers to provide data that provide better parameters for such
comparisons.
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